Background Both tuberculosis (TB) and diabetes mellitus (DM) are major public health problems threatening global health. Drug-resistant TB (DR-TB) and impaired immunity caused by DM make controlling TB more difficult. Methods We searched PubMed, Excerpta Medica Database (EMBASE), Web of Science, ScienceDirect and Cochrance Library for literature published in English until July 2022. Papers were limited to those reporting the association between DM and treatment outcomes among DR-TB and multidrug-resistant TB (MDR-TB) patients. The strength of association was presented as odds ratios (ORs) and their 95% confidence intervals (CIs) using the fixed-effects or random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed for the analysis. Results A total of twenty-five studies involving 16,905 DR-TB patients were included in the meta-analysis, of which 10,124 (59.88%) participants were MDR-TB patients, and 1,952 (11.54%) had DM history. In DR-TB patients, the pooled OR was 1.56 (95% Cl: 1.24–1.96) for unsuccessful outcomes, 0.64 (95% Cl: 0.44–0.94) for cured treatment outcomes, 0.63 (95% Cl: 0.46–0.86) for completed treatment, and 1.28 (95% Cl: 1.03–1.58) for treatment failure. Among MDR-TB patients, the pooled OR was 1.57 (95% Cl: 1.20–2.04) for unsuccessful treatment outcomes, 0.55 (95% Cl: 0.35–0.87) for cured treatment outcomes, 0.66 (95% Cl: 0.46–0.93) for completed treatment and 1.37 (95% Cl: 1.08–1.75) for treatment failure. Conclusion DM is a risk factor for adverse outcomes of DR-TB or MDR-TB patients. Controlling hyperglycemia may contribute to the favourable prognosis of TB.
Background Both tuberculosis (TB) and diabetes mellitus (DM) are major public health problems threatening global health. Drug-resistant TB (DR-TB) and impaired immunity caused by DM make controlling TB more difficult. Methods We searched PubMed, Excerpta Medica Database (EMBASE), Web of Science, ScienceDirect and Cochrance Library for literature published in English until July 2022. Papers were limited to those reporting the association between DM and treatment outcomes among DR-TB and multidrug-resistant TB (MDR-TB) patients. The strength of association was presented as odds ratios (ORs) and their 95% confidence intervals (CIs) using the fixed-effects or random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed for the analysis. Results A total of twenty-five studies involving 16,905 DR-TB patients were included in the meta-analysis, of which 10,124 (59.88%) participants were MDR-TB patients, and 1,952 (11.54%) had DM history. In DR-TB patients, the pooled OR was 1.56 (95% Cl: 1.24–1.96) for unsuccessful outcomes, 0.64 (95% Cl: 0.44–0.94) for cured treatment outcomes, 0.63 (95% Cl: 0.46–0.86) for completed treatment, and 1.28 (95% Cl: 1.03–1.58) for treatment failure. Among MDR-TB patients, the pooled OR was 1.57 (95% Cl: 1.20–2.04) for unsuccessful treatment outcomes, 0.55 (95% Cl: 0.35–0.87) for cured treatment outcomes, 0.66 (95% Cl: 0.46–0.93) for completed treatment and 1.37 (95% Cl: 1.08–1.75) for treatment failure. Conclusion DM is a risk factor for adverse outcomes of DR-TB or MDR-TB patients. Controlling hyperglycemia may contribute to the favourable prognosis of TB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.